CIBC Private Wealth Group
ANIK icon

CIBC Private Wealth Group’s Anika Therapeutics ANIK Stock Holding History

CIBC Private Wealth Group’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-235
Closed -$8K – 1004
2018
Q2 		$8K Sell
235
-14,210
-98% -$585K ﹤0.01% 1611
2018
Q1 		$718K Sell
14,445
-1,790
-11% -$101K ﹤0.01% 704
2017
Q4 		$875K Buy
16,235
+385
+2% +$21.3K ﹤0.01% 679
2017
Q3 		$919K Buy
+15,850
New +$829K ﹤0.01% 661

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
EC
Engaged Capital Newport Beach, California $327M AUM 22.96% 1-Year Est. Return
AAM
AMI Asset Management Los Angeles, California $1.74B AUM 26.89% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

CIBC Private Wealth Group's ANIK Position: Q3 2018 in Review

CIBC Private Wealth Group sold out of Anika Therapeutics (ANIK) in Q3 2018, closing a stake of 235 shares — an estimated $8K sold.

CIBC Private Wealth Group first reported a position in ANIK in Q3 2017 and held it in 4 quarters. The position peaked at $919K in Q3 2017. 161 funds tracked by Wall St. Rank hold ANIK as of Q3 2018.

  • CIBC Private Wealth Group reported no remaining Anika Therapeutics position as of Q3 2018 after selling out during the quarter.
  • CIBC Private Wealth Group sold 235 Anika Therapeutics shares in Q3 2018, an estimated $8K.
  • CIBC Private Wealth Group first reported a position in Anika Therapeutics in Q3 2017 and held it in 4 quarters.
  • CIBC Private Wealth Group's Anika Therapeutics position peaked at $919K in Q3 2017.
  • 161 funds tracked by Wall St. Rank held Anika Therapeutics as of Q3 2018.

Based on CIBC Private Wealth Group's 13F filing for Q3 2018, filed 14 Nov 2018.